Libtayo is the first treatment approved for metastatic or locally advanced cutaneous squamous cell carcinoma (CSCC). Libtayo is marketed by a joint venture between Sanofi and Regeneron.
What is the ingredient in Libtayo?
The active ingredient in Libtayo is cemiplimab, a PD-1 (programmed cell death protein-1) blocker.1
How does Libtayo work?
PD-1 is a receptor found on specific immune system cells, including T cells, and on some cancer cells. When activated, this pathway can turn off the immune system’s action of attacking cells. Cancer cells have mutations (changes) that enable them to evade the immune system and grow uncontrollably, and some cancers use the PD-1 pathway.2 Libtayo blocks this pathway, enabling the immune system to better fight off these cancers.1
What are the possible side effects of Libtayo?
The most common side effects experienced by patients receiving Libtayo include:1
Libtayo may cause serious side effects, including causing the immune system to attack healthy organs or tissues in the body. Some reactions have been life-threatening or may lead to death, including lung problems, intestinal problems, liver problems, hormone gland problems, skin problems, and kidney problems.1
Things to know about Libtayo
While receiving Libtayo, patients should be monitored for infusion-related reactions.1 Infusion-related reactions are a rare but potentially serious hypersensitivity (allergic) reaction, which may cause symptoms such as itching, fever, chills, and difficulty breathing. Treatment for infusion-related reactions may involve other medications or slowing the infusion rate.3
Libtayo is given as an intravenous (IV) infusion over 30 minutes. The recommended dose of Libtayo is 350 mg given once every three weeks, until disease progression or unacceptable toxicity (the side effects become intolerable).1
Libtayo prescribing information. Available at https://www.regeneron.com/sites/default/files/Libtayo_FPI.pdf. Accessed 10/10/18.
Immune checkpoint inhibitors to treat cancer. American Cancer Society. Available at https://www.cancer.org/treatment/treatments-and-side-effects/treatment-types/immunotherapy/immune-checkpoint-inhibitors.html. Accessed 10/10/18.
McBride A, Ngo N, Campen C. Infusion-related reactions. The Oncology Nurse. http://www.theoncologynurse.com/top-issues/2010-issues/may-vol-3-no-3/10516-top-10516. Accessed 10/10/18.